explore -WSS

explore

author：knowledge 2025-09-30 20:48:08 - browse：8716

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Judge schedules Friday hearing on proposed protective order in Jan. 6 case

knowledge

hotspot

WSS

Pumping milk in bathrooms at health conferences is common

There's an unseen cost to disruptive road

To bolster infectious disease surveillance, genomics powerhouses team up

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

HPV vaccine, cervical cancer study delivers historic results

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Peter Hotez and the public health issue of online harassment

Former Georgia lieutenant governor says he received grand jury subpoena

What does generative AI mean for health care? We asked experts

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

Affirmative action in medical school literally saved lives

Pumping milk in bathrooms at health conferences is common

Cancer drug shortages should be causing more outrage

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Hepatitis C has a cure — but many Americans still lack access to it

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

hotspot

Update the Apgar Score to remove skin color

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Flu vaccine reformulation won't be easy, manufacturers warn

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Judge rejects Trump's counterclaim against E. Jean Carroll

FDA endorses new sterilization method for medical devices

leisure time

knowledge

hotspot

entertainment